← Back to Search

18F-DOPA PET/CT Imaging Optimization

Phase 3
Recruiting
Led By Jonathan Abele, MD
Research Sponsored by University of Alberta
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Pediatric (less than 18 years old) or Adult patients (18 or older) with known or clinically suspected neuroendocrine tumor
Adult patients (18 or older) with a clinical suspicion of Parkinson's disease or Lewy body dementia
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 1 month of pet/ct scan
Awards & highlights

Study Summary

This trial is looking at using 18F-DOPA PET/CT imaging in specific patient populations to see if it can help optimize images and identify gallbladder activity patterns.

Who is the study for?
This trial is for children and adults with certain conditions like congenital hyperinsulinism, neuroendocrine tumors, brain tumors, Parkinson's disease or Lewy body dementia. It excludes pregnant individuals, those over 225 kg, patients who can't lie flat for the scan duration or give consent, and young kids who can't be sedated safely.Check my eligibility
What is being tested?
The study tests how well a PET/CT imaging technique works using an injection of Furosemide and a radioactive drug called 18F-DOPA. The goal is to optimize images for better diagnosis in various diseases including brain tumors and Parkinson's.See study design
What are the potential side effects?
Possible side effects from the Furosemide injection may include dehydration or electrolyte imbalance. The radioactive drug used in PET/CT scans has minimal side effects but might cause slight discomfort at the injection site.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am under or over 18 and may have a neuroendocrine tumor.
Select...
I am an adult suspected to have Parkinson's disease or Lewy body dementia.
Select...
I am under 18 and have been diagnosed with congenital hyperinsulinism.
Select...
I am under or over 18 with a brain tumor.
Select...
I am under 18 and have been diagnosed with neuroblastoma.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 1 month of pet/ct scan
This trial's timeline: 3 weeks for screening, Varies for treatment, and within 1 month of pet/ct scan for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Assessment of bladder activity
Assessment of bladder activity artifact
Minimum lesion detectability (SUV)
+1 more
Secondary outcome measures
Gallbladder activity pattern
Gallbladder disease questionnaire

Trial Design

1Treatment groups
Experimental Treatment
Group I: 18F-DOPA injectionExperimental Treatment2 Interventions
All enrolled participants will receive an intravenous injection of the investigational 18F-DOPA radiopharmaceutical
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Furosemide Injection
2023
Completed Phase 3
~120
18F-DOPA
2017
Completed Phase 3
~2080

Find a Location

Who is running the clinical trial?

University of AlbertaLead Sponsor
884 Previous Clinical Trials
392,099 Total Patients Enrolled
Jonathan Abele, MDPrincipal InvestigatorUniversity of Alberta
1 Previous Clinical Trials
600 Total Patients Enrolled

Media Library

18F-DOPA Clinical Trial Eligibility Overview. Trial Name: NCT04706910 — Phase 3
Parkinson's Disease Research Study Groups: 18F-DOPA injection
Parkinson's Disease Clinical Trial 2023: 18F-DOPA Highlights & Side Effects. Trial Name: NCT04706910 — Phase 3
18F-DOPA 2023 Treatment Timeline for Medical Study. Trial Name: NCT04706910 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does 18F-DOPA carry any considerable risks for those who take it?

"There is both efficacy and safety data available for 18F-DOPA, as it has progressed to Phase 3 trials. Our team rates the safety of this medication as a 3."

Answered by AI

Are patients still being accepted for this treatment program?

"That is correct, the clinical trial mentioned is still recruiting patients. The listing on clinicaltrials.gov shows that it was posted on 1/20/2021 and last edited on 4/11/2022. They are enrolling 800 people from 1 site."

Answered by AI

Do we have a solid understanding of how 18F-DOPA works?

"There are a total of 16 ongoing clinical trials for 18F-DOPA. Of these, 6 have progressed to Phase 3 testing. The majority of these trials are based in Dayton, Ohio; however, there are 44 research sites across the United States."

Answered by AI

What does 18F-DOPA help alleviate symptoms for?

"18F-DOPA can be used to combat heart failure, edema, and acute pulmonary edema."

Answered by AI
~276 spots leftby Dec 2025